BioCentury | Mar 31, 2008
Company News

BioDetection Systems B.V., Galapagos, ISA Pharmaceuticals, Notox A/S, OctoPlus, Pamgene, Pepscan Therapeutics, Royal Numico N.V., Schering-Plough, Solvay, Top I

...will focus on exploiting toll-like receptors (TLRs) to treat various diseases. Organon, Pepscan, Notox, BioDetection, PamGene...
...Leiden, the Netherlands Notox A/S , Herlev, Denmark OctoPlus N.V. (Euronext:OCTO), Leiden, the Netherlands PamGene B.V....
BioCentury | Jan 21, 2008
Company News

Invitrogen, University of Queensland, Pamgene sales and marketing update

...Invitrogen and PamGene will co-market Invitrogen's nuclear hormone receptor proteins and Lanthascreen assay technology with PamGene's...
...terms were not disclosed. Invitrogen Corp. (NASDAQ:IVGN), Carlsbad, Calif. University of Queensland , Brisbane, Australia PamGene B.V....
BioCentury | Mar 13, 2006
Company News

PamGene International B.V., J&J deal

...will use PamGene's microarray-based kinase activity profiling and cellular inhibition assays in its research programs. PamGene...
BioCentury | Jan 3, 2005
Finance

Europe's potential IPOs

...Newron $24.8 7/23/02 Ph III Nycomed NA NA Mkt Orexo $6.0 8/17/04 Ph II done PamGene...
BioCentury | Jul 19, 2004
Company News

PamGene International B.V., University of Nottingham deal

...and will later offer a service through a spinout company from its Institute of Genetics. PamGene...
BioCentury | Jun 28, 2004
Company News

Jerini, PamGene International B.V. deal

...Microarray company PamGene and Jerini Peptide Technology, a division of Jerini, partnered to combine their respective...
...combine their respective kinase technologies to develop a kinase inhibitor screening platform. Under the deal, PamGene...
...PamGene will pay Jerini Peptide fees for peptides plus royalties. Jerini AG , Berlin, Germany PamGene...
BioCentury | Jun 22, 2004
Company News

PamGene, Jerini kinase deal

...Microarray company PamGene (Den Bosch, the Netherlands) and Jerini Peptide Technology, a division of Jerini (Berlin...
...combine their respective kinase technologies to develop a kinase inhibitor screening platform. Under the deal, PamGene...
...which will contain four microarrays -- for kinase inhibitor compound screening, lead generation and optimization. PamGene...
BioCentury | May 31, 2004
Company News

Innogenetics NV, Pamgene deal

...INNX licensed exclusive rights from PamGene to its Pamstation 12 instrumentation and microarray technology to develop...
...include oncology diagnostics. INNX expects the first set of assays to be available in 2006. PamGene...
...an upfront payment and is eligible for milestones and royalties. Innogenetics NV (Euronext:INNX), Ghent, Belgium PamGene B.V....
BioCentury | May 27, 2004
Company News

Innogenetics, PamGene diagnostics deal

...Innogenetics (Euronext:INNX) licensed exclusive rights from PamGene (Hertogenbosch, the Netherlands) to its Pamstation 12 instrumentation and...
...include oncology diagnostics. INNX expects the first set of assays to be available in 2006. PamGene...
BioCentury | Dec 22, 2003
Company News

Pamgene scientific advisory board update

PamGene B.V. , Hertogenbosch, the Netherlands Business: Microarrays Appointed: Bertrand Jordan, retired director of CIML; Daniel Chan, professor of pathology, oncology, urology and radiology at Johns Hopkins University Medical School; Herb Heyneker, former CTO of Protein...
Items per page:
1 - 10 of 25
BioCentury | Mar 31, 2008
Company News

BioDetection Systems B.V., Galapagos, ISA Pharmaceuticals, Notox A/S, OctoPlus, Pamgene, Pepscan Therapeutics, Royal Numico N.V., Schering-Plough, Solvay, Top I

...will focus on exploiting toll-like receptors (TLRs) to treat various diseases. Organon, Pepscan, Notox, BioDetection, PamGene...
...Leiden, the Netherlands Notox A/S , Herlev, Denmark OctoPlus N.V. (Euronext:OCTO), Leiden, the Netherlands PamGene B.V....
BioCentury | Jan 21, 2008
Company News

Invitrogen, University of Queensland, Pamgene sales and marketing update

...Invitrogen and PamGene will co-market Invitrogen's nuclear hormone receptor proteins and Lanthascreen assay technology with PamGene's...
...terms were not disclosed. Invitrogen Corp. (NASDAQ:IVGN), Carlsbad, Calif. University of Queensland , Brisbane, Australia PamGene B.V....
BioCentury | Mar 13, 2006
Company News

PamGene International B.V., J&J deal

...will use PamGene's microarray-based kinase activity profiling and cellular inhibition assays in its research programs. PamGene...
BioCentury | Jan 3, 2005
Finance

Europe's potential IPOs

...Newron $24.8 7/23/02 Ph III Nycomed NA NA Mkt Orexo $6.0 8/17/04 Ph II done PamGene...
BioCentury | Jul 19, 2004
Company News

PamGene International B.V., University of Nottingham deal

...and will later offer a service through a spinout company from its Institute of Genetics. PamGene...
BioCentury | Jun 28, 2004
Company News

Jerini, PamGene International B.V. deal

...Microarray company PamGene and Jerini Peptide Technology, a division of Jerini, partnered to combine their respective...
...combine their respective kinase technologies to develop a kinase inhibitor screening platform. Under the deal, PamGene...
...PamGene will pay Jerini Peptide fees for peptides plus royalties. Jerini AG , Berlin, Germany PamGene...
BioCentury | Jun 22, 2004
Company News

PamGene, Jerini kinase deal

...Microarray company PamGene (Den Bosch, the Netherlands) and Jerini Peptide Technology, a division of Jerini (Berlin...
...combine their respective kinase technologies to develop a kinase inhibitor screening platform. Under the deal, PamGene...
...which will contain four microarrays -- for kinase inhibitor compound screening, lead generation and optimization. PamGene...
BioCentury | May 31, 2004
Company News

Innogenetics NV, Pamgene deal

...INNX licensed exclusive rights from PamGene to its Pamstation 12 instrumentation and microarray technology to develop...
...include oncology diagnostics. INNX expects the first set of assays to be available in 2006. PamGene...
...an upfront payment and is eligible for milestones and royalties. Innogenetics NV (Euronext:INNX), Ghent, Belgium PamGene B.V....
BioCentury | May 27, 2004
Company News

Innogenetics, PamGene diagnostics deal

...Innogenetics (Euronext:INNX) licensed exclusive rights from PamGene (Hertogenbosch, the Netherlands) to its Pamstation 12 instrumentation and...
...include oncology diagnostics. INNX expects the first set of assays to be available in 2006. PamGene...
BioCentury | Dec 22, 2003
Company News

Pamgene scientific advisory board update

PamGene B.V. , Hertogenbosch, the Netherlands Business: Microarrays Appointed: Bertrand Jordan, retired director of CIML; Daniel Chan, professor of pathology, oncology, urology and radiology at Johns Hopkins University Medical School; Herb Heyneker, former CTO of Protein...
Items per page:
1 - 10 of 25